Liftstream is an executive search recruitment company in the life sciences sector
UK aiming to boost regenerative medicine
Authored by James Sheppard
Posted in M&A Finance and Funding
Tagged cell sorter, Cell Therapy, commercialisation, David Willets, development, funding, London Biotech, One Nucleus, Oxford Biotech, regenerative medicine, research, science, Scottish Centre for Regenerative Medicine, stem cell research, Stevenage Biotech, UCL Institute of Ophthalmology, UK, UK government, UK Regenerative Medicine Platform, UKRMP
Leave a comment
Isis gains milestone from GSK for rare disease trial and Aegerion takes them on in HoFH
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Aegerion, antisense drugs, clinical studies, commercialisation, familial amyloid polyneuropathy, Genzyme, GSK, HoFH, homozygous familial hypercholesterolemia, Isis Pharmaceuticals, ISIS-TTRRX, Kynamro, milestone payments, Orphan drugs, phase 2/3 studies, rare diseases, transthyretin amyloidosis
Leave a comment
Aegerion and NPS Pharmaceuticals begin rare disease product launches
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Aegerion Pharma, CHMP positive opinion, commercial opportunities, commercialisation, Dan Rader, Dick Gregg, EMA, europe, Gattex, HoFH, Juxtapid, LOJUXTA, novel therapies, NPS pharma, orphan designation, Orphan drugs, Rare Disease, Revestive, short bowel syndrome, Takeda, USA
Leave a comment
AstraZeneca still fishing for deals
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged AlphaCore, Amarin, AstraZeneca, blockbuster, clinical development, combination, commercialisation, Crestor, Epanova, europe, fish oil, generic competition, GSK, Horizon Discovery, Lovaza, low risk, M&A, Moderna Therapeutics, Omthera Pharma, partnering deals, Pascal Soriot, Pipeline, purchases, statins, USA, Vascepa, very high triglycerides
Leave a comment